Halopropane
 | |
| Systematic (IUPAC) name | |
|---|---|
| 3-Bromo-1,1,2,2-tetrafluoropropane | |
| Clinical data | |
| Trade names | Tebron |
| Identifiers | |
| 679-84-5 | |
| None | |
| PubChem | CID 69623 |
| ChemSpider | 62826 |
| Chemical data | |
| Formula | C3H3BrF4 |
| 194.954 g/mol | |
|
SMILES
| |
| |
Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed.[1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane.[2][3][4]
See also
References
- ↑ Nigel R. Webster; Helen F. Galley (22 August 2013). Landmark Papers in Anaesthesia. OUP Oxford. pp. 70–. ISBN 978-0-19-163319-5.
- ↑ Acta anaesthesiologica Belgica. Acta Medica Belgica. 1974.
- ↑ Sanford L. Klein (1993). A glossary of anesthesia and related terminology. Springer-Verlag. ISBN 978-0-387-97831-4.
- ↑ Earl J. Catcott; J. F. Smithcors (1973). Progress in canine practice. American Veterinary Publications.
| ||||||||||||||||||||||||||||||||||||||||||||||